Singh, J. C., Mamtani, A., Barrio, A., Morrow, M., Sugarman, S., Jones, L. W., . . . Dang, C. (2017). Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2‐Positive Early Stage Breast Cancer: A Single Center Experience. Oncologist.
Styl ChicagoSingh, Jasmeet C., et al. "Pathologic Complete Response With Neoadjuvant Doxorubicin and Cyclophosphamide Followed By Paclitaxel With Trastuzumab and Pertuzumab in Patients With HER2‐Positive Early Stage Breast Cancer: A Single Center Experience." Oncologist 2017.
Citace podle MLASingh, Jasmeet C., et al. "Pathologic Complete Response With Neoadjuvant Doxorubicin and Cyclophosphamide Followed By Paclitaxel With Trastuzumab and Pertuzumab in Patients With HER2‐Positive Early Stage Breast Cancer: A Single Center Experience." Oncologist 2017.